Medicamen Biotech Ltd.

BSE: MEDICAMEQ531146ISIN INE646B01010

Healthcare
Pharmaceuticals
BSE Healthcare

Share price

₹263.90+1.60 (+0.61%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹454.00
52W low: ₹210.10
Off 52W high: -41.87%
1M return: -14.53%
3M return: +8.56%
6M return: -9.79%
1Y return: -31.38%
20D avg volume: 1,719
50 DMA: ₹288.70
200 DMA: ₹276.92

Key ratios Consolidated

Market cap: ₹357.92 Cr
Current price: ₹263.90
52W high / low: ₹454.00 / ₹210.10
Face value: ₹10.00
P/E: 36.96
P/B: 1.30
EPS (TTM): ₹7.14
Book value / share: ₹203.17
ROE: —
ROCE: 5.40%
Operating margin: —
Net margin: —
Debt / equity: 0.17
Net debt: ₹16.52 Cr
Interest cover: 4.42
Dividend yield: 0.38%
Dividend / share (TTM): ₹1.00
Payout: 14.01%
Cash conversion cycle: 206.5 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	47.90	60.65	46.91	47.17	43.05	29.61	45.14	44.74	43.05	47.32	46.50	43.54
	0.86	1.74	0.54	0.37	0.47	5.23	0.14	0.29	0.59	0.57	0.83	0.55
	48.76	62.38	47.44	47.54	43.52	34.84	45.28	45.03	43.63	47.89	47.33	44.09
	46.19	57.32	45.33	44.86	41.38	32.35	41.41	43.08	42.08	45.23	44.06	41.63
	22.61	26.09	21.69	21.97	24.60	11.52	28.52	28.94	21.67	21.82	29.10	27.67
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	9.31	9.40	8.37	8.83	8.09	8.40	8.01	7.63	7.84	8.39	8.01	7.10
	0.83	0.38	0.97	0.99	1.15	0.65	0.76	1.04	0.71	1.89	0.65	0.91
	1.79	1.73	1.83	1.86	1.80	0.48	2.21	2.61	1.77	1.77	1.80	1.82
	13.14	13.61	10.45	10.03	7.63	9.06	8.11	7.35	7.67	9.58	8.62	8.65
	2.57	5.06	2.11	2.68	2.13	2.49	3.88	1.96	1.56	2.66	3.27	2.46
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	2.57	5.06	2.11	2.68	2.13	2.49	3.88	1.96	1.56	2.66	3.27	2.46
	0.73	0.61	0.48	0.57	0.53	0.63	0.95	1.05	0.76	0.61	1.24	0.99
	1.85	4.45	1.64	2.11	1.60	1.86	2.92	0.90	0.80	2.04	2.03	1.48
	1.36	3.28	1.21	1.56	1.18	1.47	2.30	0.71	0.63	1.61	1.60	1.17
Key metrics
	5.19	7.17	4.91	5.53	5.08	3.62	6.85	5.61	4.04	6.32	5.72	5.19
	10.80%	11.80%	10.50%	11.70%	11.80%	12.20%	15.20%	12.50%	9.40%	13.40%	12.30%	11.90%
	3.90%	7.30%	3.50%	4.50%	3.70%	6.30%	6.50%	2.00%	1.90%	4.30%	4.40%	3.40%
	—	1.90%	—	1.30%	—	1.40%	—	—	—	—	—	—
	11.30%	104.80%	3.90%	5.40%	0.00%	-37.40%	-2.90%	2.80%	—	—	—	—
	15.60%	139.20%	-43.80%	134.40%	100.00%	-8.80%	43.80%	-39.20%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	202.63	197.77	162.55	179.31	140.87	115.44
	3.51	3.11	6.24	2.33	2.46	1.72
	206.12	200.88	168.79	181.63	143.33	117.17
	193.70	188.90	158.91	168.56	126.28	99.07
	92.36	94.35	90.65	104.70	81.80	55.69
	0.00	0.00	0.00	—	—	—
	35.91	34.69	31.87	30.07	20.44	14.50
	3.17	3.50	3.16	4.40	2.92	1.40
	7.21	7.22	7.07	7.09	6.37	5.77
	47.23	41.72	32.20	34.40	24.46	25.04
	12.42	11.98	9.88	13.08	17.05	18.09
	0.00	0.00	0.00	0.00	0.00	0.00
	12.42	11.98	9.88	13.08	17.05	18.09
	2.39	2.19	3.32	3.58	2.32	3.20
	10.05	9.80	6.56	9.49	14.73	14.90
	7.41	7.22	5.16	7.50	11.82	12.19
Key metrics
	22.80	22.70	20.11	24.57	26.34	25.26
	11.25%	11.50%	12.40%	13.70%	18.70%	21.90%
	4.96%	5.00%	4.00%	5.30%	10.50%	12.90%
	—	5.40%	6.00%	—	—	—
	24.66%	21.70%	-9.30%	27.30%	22.00%	—
	38.05%	49.40%	-30.90%	-35.60%	-1.10%	—
	—	-37.95	-9.26	—	—	—
	—	-3.38	-1.10	—	—	—
	—	0.17	0.16	—	—	—
	—	16.52	29.49	—	—	—
	—	206.5	198.5	—	—	—
Balance sheet
	—	371.99	296.88	—	—	—
	—	223.73	164.55	—	—	—
	—	31.26	3.76	—	—	—
	—	81.83	68.90	—	—	—
	—	70.08	62.14	—	—	—
	—	84.09	86.12	—	—	—
	—	40.01	42.60	—	—	—
	—	87.92	78.17	—	—	—
	—	47.78	33.25	—	—	—
	—	41.63	29.52	—	—	—
	—	6.15	3.73	—	—	—
	—	275.55	212.78	—	—	—
Cash flow
	—	-33.17	-7.19	—	—	—
	—	-3.04	-1.89	—	—	—
	—	63.72	-1.94	—	—	—
	—	4.78	2.07	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	43.85	54.68	43.49	42.23	38.45	26.00	41.14	42.84	41.48	45.01	44.20	42.67
	0.86	1.73	0.54	0.37	0.47	5.22	0.14	0.29	0.57	0.54	0.83	0.55
	44.71	56.41	44.03	42.60	38.92	31.21	41.28	43.13	42.06	45.55	45.03	43.22
	41.46	52.88	40.94	39.83	36.75	28.18	37.80	39.88	39.04	41.83	41.03	39.22
	22.08	25.43	21.25	21.26	23.88	10.91	27.88	28.62	21.42	22.65	28.72	27.51
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	6.22	6.24	5.53	5.71	5.31	5.52	5.44	5.13	5.48	5.88	5.77	5.23
	0.64	0.60	0.78	0.84	0.56	0.62	0.73	1.01	0.68	1.87	0.65	0.91
	1.74	1.73	1.75	1.81	1.77	0.47	2.17	2.57	1.74	1.77	1.76	1.80
	12.26	12.78	9.61	9.03	7.12	8.52	7.67	7.05	7.34	9.10	8.24	8.30
	3.26	3.53	3.08	2.77	2.17	3.04	3.48	3.25	3.02	3.73	4.01	4.00
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	3.26	3.53	3.08	2.77	2.17	3.04	3.48	3.25	3.02	3.73	4.01	4.00
	0.73	0.56	0.49	0.56	0.53	0.63	0.95	0.98	0.76	0.62	1.24	0.99
	2.53	2.97	2.59	2.21	1.64	2.41	2.52	2.27	2.26	3.10	2.77	3.01
	1.86	2.19	1.91	1.63	1.21	1.90	1.98	1.78	1.78	2.45	2.19	2.38
Key metrics
	5.64	5.86	5.61	5.42	4.50	4.13	6.38	6.83	5.44	7.37	6.42	6.71
	12.90%	10.70%	12.90%	12.80%	11.70%	15.90%	15.50%	15.90%	13.10%	16.40%	14.50%	15.70%
	5.80%	5.40%	6.00%	5.20%	4.30%	9.30%	6.10%	5.30%	5.40%	6.90%	6.30%	7.10%
	—	1.50%	—	1.30%	—	1.70%	—	—	—	—	—	—
	14.00%	110.30%	5.70%	-1.40%	-7.30%	-42.20%	-6.90%	0.40%	—	—	—	—
	54.30%	23.20%	2.80%	-2.60%	-27.40%	-22.30%	-9.00%	-24.60%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	184.25	178.85	151.46	172.39	137.88	115.44
	3.50	3.10	6.23	2.30	2.46	1.72
	187.75	181.95	157.69	174.69	140.35	117.17
	175.11	170.40	144.91	157.80	123.01	99.06
	90.02	91.81	88.83	104.70	81.80	55.69
	0.00	0.00	0.00	—	—	—
	23.70	22.79	21.57	22.12	18.57	14.50
	2.86	2.78	3.05	4.38	2.92	1.40
	7.03	7.06	6.95	7.01	6.35	5.77
	43.68	38.53	30.58	32.92	23.66	—
	12.64	11.55	12.78	16.89	17.33	18.10
	0.00	0.00	0.00	—	—	—
	12.64	11.55	12.78	16.89	17.33	18.10
	2.34	2.14	3.32	3.59	2.33	3.20
	10.30	9.41	9.46	13.30	15.00	14.91
	7.59	6.94	7.44	10.50	12.04	12.20
Key metrics
	22.53	21.39	22.78	28.28	26.60	25.27
	12.23%	12.00%	15.00%	16.40%	19.30%	21.90%
	5.59%	5.30%	6.20%	7.70%	10.90%	12.90%
	—	5.10%	7.20%	—	—	—
	24.13%	18.10%	-12.10%	25.00%	19.40%	—
	16.52%	-0.50%	-28.90%	-11.30%	0.60%	—
	—	-29.26	-3.92	—	—	—
	—	-3.11	-0.21	—	—	—
	—	0.13	0.13	—	—	—
	—	5.86	23.63	—	—	—
	—	198.7	191.8	—	—	—
Balance sheet
	—	361.52	292.93	—	—	—
	—	206.12	153.51	—	—	—
	—	31.08	3.58	—	—	—
	—	64.91	58.62	—	—	—
	—	70.08	62.14	—	—	—
	—	83.27	85.32	—	—	—
	—	37.63	41.16	—	—	—
	—	78.65	72.58	—	—	—
	—	36.94	27.21	—	—	—
	—	36.16	26.45	—	—	—
	—	0.78	0.76	—	—	—
	—	279.73	217.38	—	—	—
Cash flow
	—	-29.26	-2.01	—	—	—
	—	-2.85	-1.72	—	—	—
	—	59.61	-7.31	—	—	—
	—	0.00	1.91	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +9.06%
Sales CAGR 5Y: —
Profit CAGR 3Y: -14.39%
Profit CAGR 5Y: —
Sales YoY (TTM): +24.13%
Profit YoY (TTM): +16.52%

Consolidated

Sales CAGR 3Y: +11.97%
Sales CAGR 5Y: —
Profit CAGR 3Y: -12.70%
Profit CAGR 5Y: —
Sales YoY (TTM): +24.66%
Profit YoY (TTM): +38.05%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 27 Oct 2026

Promoter holding: 42.57%

Quarter	27 Oct 2026	September 2026	June 2026
Promoter %	42.57%	42.57%	40.46%

Holder	Type	Holding	Previous	Change
SHIVALIK RASAYAN LIMITED	Promoter	42.57%	42.57%	0.00%
PHARMADANICA A/S	Public	9.53%	9.53%	0.00%
VERALOGIX HOLDINGS(PTY) LTD	Public	4.27%	4.27%	0.00%
GINNERUP CAPITAL APS	Public	2.52%	2.52%	0.00%
INVESTOR EDUCATION AND PROTECTION FUND AUTHORITY MINISTRY OF CORPORATE AFFAIRS	Public	1.21%	1.21%	0.00%
RAJESH MADAN	Public	1.10%	1.10%	0.00%
VIJAY AMICHAND SANGHVI	Public	1.08%	1.08%	0.00%
Growel Remedies Limited	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Medicamen Biotech Ltd.	358	263.90	36.96	5.40%	+24.66% TTM	+38.05% TTM	-31.38%

Filings & corporate actions

Recent announcements

Certificate under Regulation 74 (5) of SEBI (DP) Regulation 2018- September 30, 202626 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shivalik Rasayan Ltd & Growel Remedies Ltd26 Oct 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Outcome of the meeting of Preferential Issue Commitee of the Board of Directors of Medicamen Biotech Limited to consider and approve the allotmentb of 5,00,000 Equity Shares pursuant to ....23 Oct 2026 · Company Update / Allotment of Equity Shares
Trading Plan under SEBI (PIT) Regulations 2015 - Mr Sanjay Bansal30 Sep 2026 · Company Update / Trading Plan under SEBI (PIT) Regulations, 2015
Voting Results of 33rd Annual General Meeting - September 26, 202628 Sep 2026 · Company Update / General
Closure of Trading Window- Septemeber 30, 202628 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Outcome of 33rd Annaul general Meeting held on Saturday, September 26, 2026 at 12.00 Noon.26 Sep 2026 · AGM/EGM / AGM
Announcement under Regulation 30(LODR) - Newspaper Publication AGM 20265 Sep 2026 · Company Update / Newspaper Publication
Reg 34 (1) Annual Report3 Sep 2026 · Others / Reg. 34 (1) Annual Report
Business Responsibilty and Sustainability Report - 2025-263 Sep 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Submission of Integrated Annual Report for FY 2025-263 Sep 2026 · AGM/EGM / AGM
Notice of 33rd AGM scheduled to be held on Saturday, September 26, 2026 through video conferencing/other audio visual means ("VC/OAVM")3 Sep 2026 · AGM/EGM / AGM
The Company has fixed Saturday, September 19, 2026 as the record date for determining the entitlement of members to receive the dividend, if declared at the ensuing AGM.18 Aug 2026 · Corp. Action / Record Date
Corporate Action- Fixes Record Date as September 19, 2026 for the purpose of declaration of final dividend for FY 2025-26.17 Aug 2026 · Corp. Action / Record Date
Announcement under Regulation 30 (LODR)- Newspaper Publication for the Unaudited Standalone and Consolidated Financial Results for the Qtr ended 30.06.202617 Aug 2026 · Company Update / Newspaper Publication
Board of Directors has been approved the closure of Register of Members and Share Transfer Books from September 19, 2026 to September 25, 2026 in connection with the proposed payment of ....14 Aug 2026 · Corp. Action / Book Closure
Financial Results for the quarter ended on June 30, 2026.14 Aug 2026 · Result / Financial Results
Medicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve the Unaudited Financial ....7 Aug 2026 · Board Meeting / Board Meeting
Compliance Certificate under Reg 74(5) of SEBI (DP) Regulations, 201828 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation for closure of trading window25 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
The Board of Directors of the comoany at the meeting held on Wednesday, May 27, 2026 recommnded payment of Final Dividend of Rs. 1.00 per Equity Share of the face value of Rs. 10.00 each ....28 May 2026 · Corp. Action / Dividend
Statement of Deviation & Variation Report - March 31, 202628 May 2026 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
Announcement under Regulation 30 (LODR) - Newspaper Publication for BM held on 27.05.202628 May 2026 · Company Update / Newspaper Publication
Audited Standalone & Consolidated Financial Results for the quarter and year ended on March 31, 202627 May 2026 · Result / Financial Results
Medicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 ,inter alia, to consider and approve the audited financial results ....20 May 2026 · Board Meeting / Board Meeting
Compliance Certifcate under Reg 74 (5) of SEBI (DP) Regulation , 201816 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation regarding Incorrent Event Display on NSDL Portal6 Apr 2026 · Company Update / General
Intimation of Closure of Trading Window - March 202630 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
The company has on 27.01.2026 received a cautionery letter (Email) from NSE for observations reported by the Secretarial Auditor in ASCR for FY ended 31.03.2025.21 Feb 2026 · Company Update / General
Corrigendum- Intimation regarding completion of term of Independent Directorship of Mr Harish Pande and Mr Arun Kumar18 Feb 2026 · Company Update / Change in Management
Announcement under Regulation 30 (LODR) - Newspaper Publication16 Feb 2026 · Company Update / Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligatons and Disclosure Requirements) Regulations 2025, the Company hereby informs that Mr. Harish Pande and Mr. Arun Kumar have completed ....13 Feb 2026 · Company Update / Change in Management
Unaudited Financial Results for the quarter ended on December 31, 202513 Feb 2026 · Result / Financial Results
Medicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve the unaudited consolidated ....4 Feb 2026 · Board Meeting / Board Meeting
Compliance- Certificate under Reg 74 (5) of SEBI (DP) Regulations 201816 Jan 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Announcement under Regulation 30 (LODR) - EU approval for product registration of Paracetamol from Danish Medicine Authority with XGX Pharma - Denmark7 Jan 2026 · Company Update / General
Closure of Trading Window - For declaration of unaudited financial results for the quarter ended on December 31, 202526 Dec 2025 · Insider Trading / SAST / Closure of Trading Window
Announcement under Regulation 30 (LODR) - Newspaper Publication18 Nov 2025 · Company Update / Newspaper Publication
Financial Results for the quarter and half year ended on September 30, 202514 Nov 2025 · Result / Financial Results
Medicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve unaudited Financial Results ....5 Nov 2025 · Board Meeting / Board Meeting

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 1.0000	18 Sep 2026	19 Sep 2026	—
Final Dividend - Rs. - 1.0000	19 Sep 2025	19 Sep 2025	—
Final Dividend - Rs. - 1.0000	19 Sep 2024	—	—

Board meetings

14 Aug 2026 Board Meeting - Financial Results